Nuron Biotech acquires assets of HibTITER from Wyeth - MarketLine Financial Deals

Nuron Biotech acquires assets of HibTITER from Wyeth

Nuron Biotech acquires assets of HibTITER from Wyeth - MarketLine Financial Deals
Nuron Biotech acquires assets of HibTITER from Wyeth
Published Apr 06, 2011
2 pages — Published Apr 06, 2011
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

Nuron Biotech, Inc. has acquired assets relating to HibTITER(R) (Haemophilus b Conjugate Vaccine (Diphtheria CRM197 Protein Conjugate)) from Wyeth, LLC.

  
Source:
Document ID
MA59415_110421
Country
Ticker
PFE=US
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Nuron Biotech acquires assets of HibTITER from Wyeth" Apr 06, 2011. Alacra Store. Dec 02, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Nuron-Biotech-acquires-assets-of-HibTITER-from-Wyeth-2052-59794>
  
APA:
MarketLine Financial Deals. (2011). Nuron Biotech acquires assets of HibTITER from Wyeth Apr 06, 2011. New York, NY: Alacra Store. Retrieved Dec 02, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Nuron-Biotech-acquires-assets-of-HibTITER-from-Wyeth-2052-59794>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.